SI2710005T1 - Zaviralci tirozinske kinaze - Google Patents
Zaviralci tirozinske kinazeInfo
- Publication number
- SI2710005T1 SI2710005T1 SI201230743A SI201230743A SI2710005T1 SI 2710005 T1 SI2710005 T1 SI 2710005T1 SI 201230743 A SI201230743 A SI 201230743A SI 201230743 A SI201230743 A SI 201230743A SI 2710005 T1 SI2710005 T1 SI 2710005T1
- Authority
- SI
- Slovenia
- Prior art keywords
- tyrosine kinase
- kinase inhibitors
- inhibitors
- tyrosine
- kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161486944P | 2011-05-17 | 2011-05-17 | |
US201161514892P | 2011-08-03 | 2011-08-03 | |
US201161556336P | 2011-11-07 | 2011-11-07 | |
US201261618152P | 2012-03-30 | 2012-03-30 | |
EP12722662.9A EP2710005B1 (en) | 2011-05-17 | 2012-05-16 | Tyrosine kinase inhibitors |
PCT/US2012/038092 WO2012158764A1 (en) | 2011-05-17 | 2012-05-16 | Tyrosine kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2710005T1 true SI2710005T1 (sl) | 2017-03-31 |
Family
ID=46147109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201230743A SI2710005T1 (sl) | 2011-05-17 | 2012-05-16 | Zaviralci tirozinske kinaze |
Country Status (16)
Country | Link |
---|---|
US (2) | US8962831B2 (sl) |
EP (1) | EP2710005B1 (sl) |
JP (1) | JP5974084B2 (sl) |
KR (1) | KR102027598B1 (sl) |
CN (1) | CN103534258B (sl) |
AU (3) | AU2012255860C1 (sl) |
CA (1) | CA2836410C (sl) |
EA (1) | EA025496B1 (sl) |
ES (1) | ES2604191T3 (sl) |
HR (1) | HRP20170017T1 (sl) |
HU (1) | HUE033019T2 (sl) |
MX (1) | MX347040B (sl) |
PL (1) | PL2710005T3 (sl) |
PT (1) | PT2710005T (sl) |
SI (1) | SI2710005T1 (sl) |
WO (1) | WO2012158764A1 (sl) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120101114A1 (en) | 2007-03-28 | 2012-04-26 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
US20110224235A1 (en) | 2008-07-16 | 2011-09-15 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
CA3007787C (en) | 2010-06-03 | 2020-03-10 | Pharmacyclics Llc | The use of inhibitors of bruton's tyrosine kinase (btk) |
BR112013029508B1 (pt) * | 2011-05-17 | 2022-05-03 | Principia Biopharma, Inc. | Composto, composição farmacêutica, e, uso do referido composto |
US9376438B2 (en) | 2011-05-17 | 2016-06-28 | Principia Biopharma, Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
CA2836410C (en) | 2011-05-17 | 2019-08-20 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
WO2013010136A2 (en) | 2011-07-13 | 2013-01-17 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
MY187999A (en) | 2012-06-04 | 2021-11-08 | Pharmacyclics Llc | Crystalline forms of a bruton's tyrosine kinase inhibitor |
DK2861599T3 (da) * | 2012-06-18 | 2020-03-02 | Principia Biopharma Inc | Reversible kovalente pyrrolo- eller pyrazolopyrimidiner, der er nyttige til behandling af cancer og autoimmunsygdomme |
WO2014018567A1 (en) | 2012-07-24 | 2014-01-30 | Pharmacyclics, Inc. | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
US9573958B2 (en) | 2012-08-31 | 2017-02-21 | Principia Biopharma, Inc. | Benzimidazole derivatives as ITK inhibitors |
KR102203990B1 (ko) * | 2012-09-10 | 2021-01-18 | 프린시피아 바이오파마, 인코퍼레이티드 | 키나제 저해제로서의 피라졸로피리미딘 화합물 |
WO2014078578A1 (en) * | 2012-11-15 | 2014-05-22 | Pharmacyclics, Inc. | Pyrrolopyrimidine compounds as kinase inhibitors |
US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
JP6204568B2 (ja) | 2013-04-25 | 2017-09-27 | ベイジーン,リミテッド | タンパク質キナーゼ阻害剤としての縮合複素環化合物 |
GB201309085D0 (en) | 2013-05-20 | 2013-07-03 | Redx Pharma Ltd | Compounds |
JP6139782B2 (ja) * | 2013-05-21 | 2017-05-31 | チャンスー メドリューション リミテッド | 置換ピラゾロピリミジン化合物、及びその薬学的に許容される塩、並びにこれらの溶媒和物、立体異性体、及び互変異性体、並びにこれらを含む医薬組成物 |
US9415050B2 (en) | 2013-08-12 | 2016-08-16 | Pharmacyclics Llc | Methods for the treatment of HER2 amplified cancer |
CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
US9624224B2 (en) | 2013-09-30 | 2017-04-18 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
PT3107544T (pt) | 2014-02-21 | 2021-01-05 | Principia Biopharma Inc | Sais e forma sólida de um inibidor de btk |
JP2017509336A (ja) | 2014-03-20 | 2017-04-06 | ファーマサイクリックス エルエルシー | ホスホリパーゼcガンマ2及び耐性に関連した変異 |
CN105017256A (zh) * | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
GB201410430D0 (en) | 2014-06-11 | 2014-07-23 | Redx Pharma Ltd | Compounds |
CN110156892B (zh) | 2014-07-03 | 2023-05-16 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
WO2016019233A1 (en) | 2014-08-01 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
US9545407B2 (en) | 2014-08-07 | 2017-01-17 | Pharmacyclics Llc | Formulations of a bruton's tyrosine kinase inhibitor |
CN105399756B (zh) * | 2014-09-05 | 2019-06-25 | 广东东阳光药业有限公司 | Btk抑制剂及其用途 |
EP3233103B1 (en) | 2014-12-18 | 2020-10-14 | Principia Biopharma Inc. | Treatment of pemphigus |
CN105820168B (zh) * | 2015-01-09 | 2018-12-04 | 上海医药工业研究院 | 一种依鲁替尼中间体的制备方法 |
CN104557945B (zh) * | 2015-01-27 | 2017-08-04 | 安润医药科技(苏州)有限公司 | 依鲁替尼合成方法 |
TW202315634A (zh) | 2015-03-03 | 2023-04-16 | 美商製藥公司 | 布魯東氏(bruton’s)酪胺酸激酶抑制劑之醫藥調配物 |
CN106146508A (zh) * | 2015-03-19 | 2016-11-23 | 浙江导明医药科技有限公司 | 优化的联合用药及其治疗癌症和自身免疫疾病的用途 |
US9717745B2 (en) | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
CN106146512B (zh) * | 2015-04-09 | 2018-07-17 | 北京睿创康泰医药研究院有限公司 | 依鲁替尼的制备方法 |
CN104844580B (zh) * | 2015-04-17 | 2017-10-20 | 中国药科大学 | 嘧啶类化合物、其制备方法及医药用途 |
CN106188062A (zh) * | 2015-05-08 | 2016-12-07 | 苏州鹏旭医药科技有限公司 | 依鲁替尼的制备方法、依鲁替尼的中间体及中间体的制备方法 |
KR102552653B1 (ko) * | 2015-06-03 | 2023-07-07 | 프린시피아 바이오파마, 인코퍼레이티드 | 티로신 키나제 억제제 |
WO2016210165A1 (en) * | 2015-06-24 | 2016-12-29 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
WO2017027883A1 (en) | 2015-08-13 | 2017-02-16 | San Diego State University Research Foundation | Atropisomerism for increased kinase inhibitor selectivity |
CA2997051C (en) * | 2015-09-01 | 2020-03-24 | Taiho Pharmaceutical Co., Ltd. | Novel pyrazolo[3,4-d]pyrimidine compound or salt thereof |
KR20180109842A (ko) | 2015-09-16 | 2018-10-08 | 록쏘 온콜로지, 인코포레이티드 | 화합물 |
CA3008488C (en) | 2015-12-16 | 2023-10-10 | Loxo Oncology, Inc. | Compounds useful as kinase inhibitors |
CN107021963A (zh) | 2016-01-29 | 2017-08-08 | 北京诺诚健华医药科技有限公司 | 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用 |
EP4321513A2 (en) | 2016-03-28 | 2024-02-14 | Incyte Corporation | Pyrrolotriazine compounds as tam inhibitors |
CN111153906B (zh) * | 2016-05-16 | 2020-09-11 | 苏州信诺维医药科技有限公司 | 作为btk抑制剂的吡唑并嘧啶衍生物及其制备方法和药物组合物 |
CN115054586A (zh) | 2016-06-29 | 2022-09-16 | 普林斯匹亚生物制药公司 | 改性的释放制剂 |
EP3481393B1 (en) | 2016-07-05 | 2021-04-14 | Beigene, Ltd. | Combination of a pd-1 antagonist and a raf inhibitor for treating cancer |
CN116478166A (zh) | 2016-08-16 | 2023-07-25 | 百济神州(苏州)生物科技有限公司 | 一种化合物的晶型、其制备和用途 |
TWI739887B (zh) | 2016-08-19 | 2021-09-21 | 英屬開曼群島商百濟神州有限公司 | 使用包含btk抑制劑的組合產品治療癌症 |
AU2017326558B2 (en) | 2016-09-19 | 2022-01-06 | Mei Pharma, Inc. | Combination therapy |
TWI774726B (zh) | 2017-01-25 | 2022-08-21 | 英屬開曼群島商百濟神州有限公司 | (S)-7-(1-(丁-2-炔醯基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氫吡唑并[1,5-a]嘧啶-3-甲醯胺的晶型、及其製備和用途 |
KR20200020902A (ko) | 2017-06-26 | 2020-02-26 | 베이진 엘티디 | 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료 |
US11377449B2 (en) | 2017-08-12 | 2022-07-05 | Beigene, Ltd. | BTK inhibitors with improved dual selectivity |
CN107722016A (zh) * | 2017-10-20 | 2018-02-23 | 尚科生物医药(上海)有限公司 | 一种无定型依鲁替尼的制备方法 |
TW201922256A (zh) | 2017-10-27 | 2019-06-16 | 中國大陸商浙江導明醫藥科技有限公司 | 治療淋巴樣惡性疾病之方法 |
CN111801334B (zh) | 2017-11-29 | 2023-06-09 | 百济神州瑞士有限责任公司 | 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤 |
KR20220124753A (ko) | 2020-01-08 | 2022-09-14 | 프린시피아 바이오파마, 인코퍼레이티드 | 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)-1H-피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카보닐]-4,4-디메틸펜트-2-엔니트릴을 포함하는 국소 약제학적 조성물 |
KR20220124752A (ko) | 2020-01-08 | 2022-09-14 | 프린시피아 바이오파마, 인코퍼레이티드 | 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)-1h-피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4,4-디메틸펜트-2-엔니트릴의 결정 형태 |
CA3175788A1 (en) | 2020-04-22 | 2021-10-28 | Claire LANGRISH | Treatment of acute respiratory distress syndrome and other disorders involving cytokine storm using btk inhibitors |
CN111481671A (zh) * | 2020-05-26 | 2020-08-04 | 华中科技大学同济医学院附属协和医院 | 酪氨酸激酶抑制剂在制备***性红斑狼疮脑病药物中的应用 |
WO2022140246A1 (en) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
EP4267186A1 (en) * | 2020-12-23 | 2023-11-01 | Yeda Research and Development Co. Ltd | Methacrylamides protein binders and uses thereof |
KR20230171975A (ko) | 2021-04-16 | 2023-12-21 | 프린시피아 바이오파마, 인코퍼레이티드 | 특정 화합물을 투여하여 약물 및 백신 유발성 면역성 혈소판 감소증을 치료하는 방법 |
US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
WO2023249980A1 (en) * | 2022-06-22 | 2023-12-28 | Genzyme Corporation | Methods of making modified btk inhibitors |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS428308Y1 (sl) | 1964-09-09 | 1967-04-27 | ||
US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
JPS5617367A (en) | 1979-07-23 | 1981-02-19 | Fuji Xerox Co Ltd | Magnetic brush developing unit |
JPS5663950A (en) | 1979-10-30 | 1981-05-30 | Mitsubishi Chem Ind Ltd | Cyclopropanecarboxylic ester |
FR2535721A1 (fr) | 1982-11-08 | 1984-05-11 | Sanofi Sa | Derives de la piperidinedione protecteurs du myocarde presentant une acticite antiarythmique, leur procede de preparation et les medicaments qui contiennent lesdits derives |
US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
CA2018801C (en) | 1990-06-12 | 2000-08-22 | Pierre Louis Beaulieu | Antiherpes peptide derivatives having a 1,4-dioxo c n-terminus |
JPH04177244A (ja) | 1990-11-10 | 1992-06-24 | Konica Corp | ハロゲン化銀写真感光材料 |
CA2033447C (en) | 1990-12-31 | 1999-08-31 | Robert Deziel | Synergistic combination for treating herpes infections |
DK0495421T3 (da) | 1991-01-15 | 1996-12-09 | Alcon Lab Inc | Anvendelse af carragenaner i topiske ophthalmiske sammensætninger |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
JPH05301838A (ja) | 1991-10-15 | 1993-11-16 | Mitsubishi Kasei Corp | スチレン誘導体 |
US5792771A (en) | 1992-11-13 | 1998-08-11 | Sugen, Inc. | Quinazoline compounds and compositions thereof for the treatment of disease |
WO1995024190A2 (en) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
JPH0827090A (ja) | 1994-05-13 | 1996-01-30 | Sumitomo Chem Co Ltd | シアノ酢酸アミド誘導体、その用途およびその製造中間体 |
HUP0001603A3 (en) | 1997-03-14 | 2004-05-28 | Basf Ag | Cycloalkylalkanecarboxamides and the production and use thereof |
US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
IL125947A0 (en) | 1997-09-17 | 1999-04-11 | American Cyanamid Co | 3-(1,2-benzisothiazol- and isoxazol-5-yl)-2,4(1h,3h)-pyrimidinedione or thione and 3-(1,2-benzisothiazol- and isoxazol-5-yl)-4(3)-pyrimidinone or thione herbicidal agents |
US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
AU780052B2 (en) | 1999-09-17 | 2005-02-24 | Abbott Gmbh & Co. Kg | Pyrazolopyrimidines as therapeutic agents |
SK12472002A3 (sk) * | 2000-03-06 | 2003-04-01 | Warner-Lambert Company | 5-Alkylpyrido[2,3-d]pyrimidínové inhibítory tyrosínových kináz |
WO2001072751A1 (en) | 2000-03-29 | 2001-10-04 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
JP3991812B2 (ja) | 2001-12-11 | 2007-10-17 | 住友化学株式会社 | エステル化合物およびその用途 |
AU2003210983A1 (en) * | 2002-02-11 | 2003-09-04 | The Brigham And Women's Hospital, Inc. | Kinase inhibitors and methods of use thereof |
NI200300043A (es) | 2002-03-28 | 2003-11-05 | Warner Lambert Co | AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA. |
GB0219024D0 (en) | 2002-08-15 | 2002-09-25 | Pfizer Ltd | Synergistic combinations |
US7419981B2 (en) | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
GB0226370D0 (en) | 2002-11-12 | 2002-12-18 | Novartis Ag | Organic compounds |
WO2004074283A1 (en) | 2003-02-21 | 2004-09-02 | Pfizer Inc. | N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors |
WO2004100868A2 (en) | 2003-04-23 | 2004-11-25 | Abbott Laboratories | Method of treating transplant rejection |
EP1620437B1 (en) * | 2003-04-29 | 2009-06-17 | Pfizer Limited | 5,7-diaminopyrazolo¬4,3-d pyrimidines useful in the traetment of hypertension |
WO2005011812A1 (en) | 2003-08-01 | 2005-02-10 | Chugai Seiyaku Kabushiki Kaisha | Cyanoamide compounds useful as malonyl-coa decarboxylase inhibithors |
WO2005023773A1 (en) | 2003-09-04 | 2005-03-17 | Pfizer Limited | Process for the preparation of substituted aryl pyrazoles |
GB0322140D0 (en) | 2003-09-22 | 2003-10-22 | Pfizer Ltd | Combinations |
CA2539976A1 (en) | 2003-09-25 | 2005-04-07 | Warner-Lambert Company Llc | Therapeutic beta aminoacids |
CA2553724A1 (en) | 2004-02-03 | 2005-08-18 | Abbott Laboratories | Aminobenzoxazoles as therapeutic agents |
KR100844864B1 (ko) * | 2004-02-27 | 2008-07-09 | 에프. 호프만-라 로슈 아게 | 헤테로아릴-융합 피라졸로 유도체 |
JP4552456B2 (ja) | 2004-02-27 | 2010-09-29 | 住友化学株式会社 | エステル化合物およびその用途 |
WO2005085210A1 (ja) | 2004-03-10 | 2005-09-15 | Ono Pharmaceutical Co., Ltd. | ニトリル化合物およびその化合物を有効成分として含有する医薬組成物 |
US7807719B2 (en) | 2004-09-14 | 2010-10-05 | Chaim Roifman | Compounds useful for modulating abnormal cell proliferation |
CA2612287C (en) | 2005-06-15 | 2011-01-25 | Pfizer Limited | Substituted arylpyrazoles for use against parasites |
US20080146643A1 (en) | 2005-06-15 | 2008-06-19 | Pfizer Limited | Combination |
US7645786B2 (en) | 2005-06-15 | 2010-01-12 | Pfizer Inc. | Substituted arylpyrazoles |
US20080176865A1 (en) | 2005-06-15 | 2008-07-24 | Pfizer Limited | Substituted arylpyrazoles |
US20070149464A1 (en) | 2005-06-15 | 2007-06-28 | Pfizer Inc. | Combination |
JPWO2007043401A1 (ja) | 2005-10-07 | 2009-04-16 | キッセイ薬品工業株式会社 | 含窒素複素環化合物およびそれを含有する医薬組成物 |
JP5193876B2 (ja) | 2005-12-02 | 2013-05-08 | バイエル・ヘルスケア・エルエルシー | オーロラキナーゼの阻害により癌を処置するために有用なピロロトリアジン誘導体 |
KR20080098490A (ko) | 2006-01-13 | 2008-11-10 | 파마시클릭스, 인코포레이티드 | 티로신 키나제 억제제 및 이의 용도 |
US8779151B2 (en) | 2006-03-31 | 2014-07-15 | The Board Of Regents Of The University Of Texas System | Orally bioavailable caffeic acid related anticancer drugs |
US7645748B2 (en) | 2006-04-03 | 2010-01-12 | Forbes Medi-Tech Inc. | Sterol/stanol phosphorylnitroderivatives and use thereof |
US20100292229A1 (en) | 2006-06-30 | 2010-11-18 | The Board Of Regents Of The University Of Texas System | Tryphostin-analogs for the treatment of cell proliferative diseases |
NZ601278A (en) * | 2006-09-22 | 2013-09-27 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
ES2403546T3 (es) | 2006-11-03 | 2013-05-20 | Pharmacyclics, Inc. | Sonda de actividad de la tirosina-cinasa de Bruton y procedimiento de utilización |
EP2086947A1 (en) | 2006-11-23 | 2009-08-12 | Novartis AG | Pyrimidines and their use as cxcr2 receptor antagonists |
JP2010522241A (ja) * | 2007-03-21 | 2010-07-01 | ブリストル−マイヤーズ スクイブ カンパニー | 増殖性疾患、アレルギー性疾患、自己免疫疾患または炎症性疾患として有用な縮合ヘテロ環化合物 |
GB2447933A (en) | 2007-03-27 | 2008-10-01 | Chemence Ltd | Cyanoacrylate monomer for forming an adhesive polymer |
CA3143428A1 (en) * | 2007-03-28 | 2008-10-09 | Pharmacyclics Llc | 8-amino-3-substituted-imidazo[1,5-a]pyrazine and use thereof as inhibitors of bruton's tyrosine kinase |
US20110224235A1 (en) * | 2008-07-16 | 2011-09-15 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
US20120028981A1 (en) | 2008-11-05 | 2012-02-02 | Principia Biopharma Inc. | Kinase Knockdown Via Electrophilically Enhanced Inhibitors |
US20100113520A1 (en) | 2008-11-05 | 2010-05-06 | Principia Biopharma, Inc. | Kinase knockdown via electrophilically enhanced inhibitors |
US8426428B2 (en) | 2008-12-05 | 2013-04-23 | Principia Biopharma, Inc. | EGFR kinase knockdown via electrophilically enhanced inhibitors |
US7718662B1 (en) | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
CN102711765A (zh) | 2009-11-16 | 2012-10-03 | 加利福尼亚大学董事会 | 激酶抑制剂 |
LT2578585T (lt) | 2010-05-31 | 2016-10-10 | Ono Pharmaceutical Co., Ltd. | Purinono darinys kaip btk kinazės inhibitorius |
CA3007787C (en) | 2010-06-03 | 2020-03-10 | Pharmacyclics Llc | The use of inhibitors of bruton's tyrosine kinase (btk) |
CN101880243A (zh) | 2010-06-04 | 2010-11-10 | 贵阳柏丝特化工有限公司 | 一种含氟氰拟除虫菊酯化合物及其合成方法与用途 |
BR112013029508B1 (pt) | 2011-05-17 | 2022-05-03 | Principia Biopharma, Inc. | Composto, composição farmacêutica, e, uso do referido composto |
US20140107151A1 (en) | 2011-05-17 | 2014-04-17 | Principia Biophama Inc. | Tyrosine kinase inhibitors |
US9376438B2 (en) | 2011-05-17 | 2016-06-28 | Principia Biopharma, Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
CA2836410C (en) | 2011-05-17 | 2019-08-20 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
AU2012275275A1 (en) | 2011-06-28 | 2014-01-23 | Pharmacyclics Llc | Methods and compositions for inhibition of bone resorption |
WO2013010136A2 (en) | 2011-07-13 | 2013-01-17 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
EA034558B1 (ru) | 2011-07-19 | 2020-02-20 | Мерк Шарп и Доум Б.В. | 4-ИМИДАЗО[1,5-a]ПИРИДАЗИН-1-ИЛ-БЕНЗАМИДЫ В КАЧЕСТВЕ Btk-ИНГИБИТОРОВ |
CA2841887A1 (en) | 2011-07-19 | 2013-01-24 | Merck Sharp & Dohme B.V. | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk - inhibitors |
CA2851808C (en) | 2011-10-19 | 2021-04-13 | Pharmacyclics, Inc. | Use of inhibitors of bruton's tyrosine kinase (btk) |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
US8501724B1 (en) | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
DK2861599T3 (da) | 2012-06-18 | 2020-03-02 | Principia Biopharma Inc | Reversible kovalente pyrrolo- eller pyrazolopyrimidiner, der er nyttige til behandling af cancer og autoimmunsygdomme |
US9572811B2 (en) | 2012-08-03 | 2017-02-21 | Principia Biopharma Inc. | Treatment of dry eye |
WO2014078578A1 (en) | 2012-11-15 | 2014-05-22 | Pharmacyclics, Inc. | Pyrrolopyrimidine compounds as kinase inhibitors |
US20140142099A1 (en) | 2012-11-20 | 2014-05-22 | Principia Biopharma Inc. | Purinone Derivatives as Tyrosine Kinase Inhibitors |
-
2012
- 2012-05-16 CA CA2836410A patent/CA2836410C/en active Active
- 2012-05-16 MX MX2013013294A patent/MX347040B/es active IP Right Grant
- 2012-05-16 EA EA201391528A patent/EA025496B1/ru not_active IP Right Cessation
- 2012-05-16 WO PCT/US2012/038092 patent/WO2012158764A1/en active Application Filing
- 2012-05-16 US US14/117,933 patent/US8962831B2/en active Active
- 2012-05-16 CN CN201280023262.9A patent/CN103534258B/zh active Active
- 2012-05-16 AU AU2012255860A patent/AU2012255860C1/en active Active
- 2012-05-16 PL PL12722662T patent/PL2710005T3/pl unknown
- 2012-05-16 JP JP2014511480A patent/JP5974084B2/ja active Active
- 2012-05-16 HU HUE12722662A patent/HUE033019T2/en unknown
- 2012-05-16 PT PT127226629T patent/PT2710005T/pt unknown
- 2012-05-16 ES ES12722662.9T patent/ES2604191T3/es active Active
- 2012-05-16 SI SI201230743A patent/SI2710005T1/sl unknown
- 2012-05-16 EP EP12722662.9A patent/EP2710005B1/en active Active
- 2012-05-16 KR KR1020137033089A patent/KR102027598B1/ko active IP Right Grant
-
2015
- 2015-01-06 US US14/590,851 patent/US20150353557A1/en not_active Abandoned
- 2015-10-19 AU AU2015243110A patent/AU2015243110B2/en active Active
-
2017
- 2017-01-05 HR HRP20170017TT patent/HRP20170017T1/hr unknown
-
2018
- 2018-07-26 AU AU2018208715A patent/AU2018208715A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US8962831B2 (en) | 2015-02-24 |
MX2013013294A (es) | 2014-04-25 |
PL2710005T3 (pl) | 2017-07-31 |
KR102027598B1 (ko) | 2019-10-01 |
AU2015243110A1 (en) | 2015-11-05 |
CA2836410C (en) | 2019-08-20 |
AU2012255860B2 (en) | 2015-07-23 |
EP2710005A1 (en) | 2014-03-26 |
EA201391528A1 (ru) | 2014-09-30 |
CN103534258A (zh) | 2014-01-22 |
JP5974084B2 (ja) | 2016-08-23 |
CA2836410A1 (en) | 2012-11-22 |
MX347040B (es) | 2017-04-10 |
WO2012158764A1 (en) | 2012-11-22 |
US20140094459A1 (en) | 2014-04-03 |
CN103534258B (zh) | 2016-09-14 |
AU2012255860A1 (en) | 2013-04-18 |
KR20140058438A (ko) | 2014-05-14 |
US20150353557A1 (en) | 2015-12-10 |
JP2014517838A (ja) | 2014-07-24 |
AU2012255860C1 (en) | 2015-12-10 |
EP2710005B1 (en) | 2016-10-05 |
EA025496B1 (ru) | 2016-12-30 |
HRP20170017T1 (hr) | 2017-02-24 |
PT2710005T (pt) | 2016-11-16 |
ES2604191T3 (es) | 2017-03-03 |
AU2015243110B2 (en) | 2018-05-24 |
HUE033019T2 (en) | 2017-11-28 |
AU2018208715A1 (en) | 2018-08-16 |
BR112013028846A2 (pt) | 2020-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI2710005T1 (sl) | Zaviralci tirozinske kinaze | |
HK1200828A1 (en) | Kinase inhibitors | |
HK1200451A1 (zh) | 蛋白激酶抑制劑 | |
HUE048834T2 (hu) | Kináz inhibitorok | |
EP2694517A4 (en) | PROTEIN KINASE INHIBITORS | |
EP2552208A4 (en) | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | |
IL228103A0 (en) | Amino-quinolines as kinase inhibitors | |
EP2552211A4 (en) | INDAZOLYL-PYRIMIDINE AS KINASEHEMMER | |
ZA201306855B (en) | Protein kinase inhibitors | |
IL229028A0 (en) | Kinase inhibitors | |
GB201009731D0 (en) | Kinase inhibitors | |
HK1199873A1 (en) | Kinase inhibitors | |
EP2685992A4 (en) | AMINO-QUINOLINES AS KINASE INHIBITORS | |
IL232234A0 (en) | Inhibitors of aminopyrimidine kinase | |
IL228928A0 (en) | Aminopyrimidine kinase inhibitors | |
GB201114851D0 (en) | Novel lim kinase inhibitors |